ATIR (Allodepleted T-cell Immunotherapeutics) is no longer being developed by Kiadis.


Kiadis announced on November 12th, 2019 that it has completed a strategic portfolio review and has decided to change its strategy and focus all resources and investments on the company’s NK-cell therapy platform and product candidates. The company will discontinue development of ATIR101 and stop its ongoing phase 3 trial.